Company: SINT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024040
Chunk: 33

Company: Sintx Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 2
Chunk 33
---
You
should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated
financial statements for the year ended December 31, 2024 and the notes thereto, along with Management’s Discussion and Analysis
of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed
separately with the U.S. Securities and Exchange Commission. This discussion and analysis contains forward-looking statements based upon
current beliefs, plans, expectations, intentions and projections that involve risks, uncertainties and assumptions, such as statements
regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could
differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth
under the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2024, and any updates
to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q and in other filings with the Securities and Exchange
Commission we may make from time-to-time.

Overview

SINTX Technologies is an advanced ceramics company formed in December 1996, that develops and commercializes materials, components, and
technologies for medical and agribiotech applications. SINTX provides biomedical solutions for medical devices specializing in silicon
nitride (Si₃N₄) for musculoskeletal and antipathogenic applications. SINTX
is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans
since 2008.

SINTX
Core Business

Biomedical
Applications: Since its inception, SINTX has been focused on medical grade silicon nitride. SINTX biomedical products have been shown to be biocompatible,
bioactive, antipathogenic, and to have superb bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted
in humans since 2008 in the U.S., Europe, South America and Asia. This established use, along with its inherent resistance to bacterial
adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot
wedges, and dental implants. More recently, in July 2025, SINTX submitted a 510(k) premarket notification